KIMS Reports ₹415M Q1 Profit, Inks Agreements with Golden Lan

HYDERABAD, India — Krishna Institute of Medical Sciences Ltd (KIMS) has reported its consolidated financial results for the June quarter, recording a net profit of ₹415 million alongside operations revenue of ₹11.8 billion. Alongside the financial results released to stock exchanges, the healthcare group announced draft Operations and Management (O&M) and Call Option agreements involving Golden Lan and Sarwottam Healthcare. The developments mark a key phase in the hospital chain’s ongoing asset-light expansion strategy across regional healthcare markets in India.

Financial Performance for the June Quarter

Krishna Institute of Medical Sciences Ltd reported robust top-line performance for the quarter ending June. According to regulatory filings submitted to the National Stock Exchange of India (NSE) and BSE Limited, consolidated revenue from operations reached ₹11.8 billion (₹1,180 crore).

The company's consolidated net profit for the June quarter stood at ₹415 million (₹41.5 crore). The revenue expansion reflects increased bed occupancy across core tertiary facilities and growing demand for specialized medical care in cardiology, oncology, neurosciences, and organ transplantation across its network.

O&M and Call Option Agreements with Golden Lan and Sarwottam Healthcare

Beyond financial disclosures, Krishna Institute of Medical Sciences Ltd has finalized draft Operations and Management (O&M) and Call Option agreements with Golden Lan and Sarwottam Healthcare.

Under the structure of the O&M agreement, KIMS will provide clinical management, operational governance, and brand overlay for clinical facilities operated under the agreement. In tandem, the Call Option agreement gives Krishna Institute of Medical Sciences Ltd the right to acquire equity stake in the partner entities under predetermined commercial conditions over time.

This dual agreement framework reflects Krishna Institute of Medical Sciences Ltd’s strategic shift toward asset-light operational models. By leveraging existing clinical infrastructure while securing purchase options, the company aims to scale bed capacity in tier-2 and tier-3 markets without committing large upfront capital expenditure.

Market and Operational Context

Headquartered in Hyderabad, Krishna Institute of Medical Sciences Ltd is one of the largest private healthcare providers in southern India, operating thousands of beds across Telangana, Andhra Pradesh, Maharashtra, Kerala, and Karnataka.

The Indian private healthcare sector has seen increasing integration as major hospital operators deploy O&M contracts and call option arrangements to accelerate geographic expansion. Investors and market analysts closely monitor these structural agreements as indicators of long-term margin trajectory and capital allocation efficiency.

For patients and local communities, the expansion of Krishna Institute of Medical Sciences Ltd into new locations via operational agreements brings advanced tertiary and quaternary healthcare closer to home, reducing the requirement for patients to travel long distances to major metropolitan centers for critical medical procedures.

Official Sources Section

All financial data, agreement drafts, and corporate developments referenced in this report are based on official announcements, regulatory filings with the National Stock Exchange of India (NSE) and BSE Limited, and official corporate press releases issued by Krishna Institute of Medical Sciences Ltd.

Statement from Management

According to officials familiar with the regulatory filings, the partnership framework with Golden Lan and Sarwottam Healthcare aligns directly with the group's disciplined growth mandate.

"According to officials, entering into operational and management agreements alongside call options allows the group to extend its high-quality clinical protocols to newer geographic hubs while maintaining capital discipline and preserving balance sheet flexibility."

Why It Matters

The combination of solid Q1 revenue figures and new strategic agreements highlights key practical implications across multiple stakeholders:

• For Investors: The ₹11.8 billion revenue stream demonstrates sustained patient volume, while O&M agreements reduce capital intensity, supporting return on capital employed (ROCE) over time.

• For Patients: Access to advanced medical specialties—including cardiology, oncology, and critical care—is broadened across non-metro regions through KIMS-managed facilities.

• For the Healthcare Sector: Demonstrates the continuing trend toward consolidated brand networks and asset-light hospital operations across India.

Key Facts at a Glance

• June Quarter Revenue: Consolidated operations revenue reached ₹11.8 billion (₹1,180 crore).

• June Quarter Net Profit: Consolidated net profit totaled ₹415 million (₹41.5 crore).

• Strategic Agreements: Executed draft O&M and Call Option agreements with Golden Lan and Sarwottam Healthcare.

• Corporate Strategy: Focuses on asset-light expansion to scale bed capacity efficiently.

Frequently Asked Questions (FAQ)

What was the revenue of Krishna Institute of Medical Sciences Ltd for the June quarter?

Krishna Institute of Medical Sciences Ltd reported consolidated revenue from operations of ₹11.8 billion (₹1,180 crore) for the June quarter.

What is the net profit reported by Krishna Institute of Medical Sciences Ltd for the June quarter?

The hospital chain recorded a consolidated net profit of ₹415 million (₹41.5 crore) for the June quarter.

What are the O&M and Call Option agreements signed with Golden Lan and Sarwottam Healthcare?

The agreements allow Krishna Institute of Medical Sciences Ltd to manage day-to-day healthcare operations and clinical delivery while retaining an option (Call Option) to purchase equity stakes in the partner entities in the future.

How do these agreements benefit patients?

Patients gain local access to Krishna Institute of Medical Sciences Ltd’s clinical expertise and specialized medical care without needing to relocate to major metropolitan centers for advanced treatment.

Source: Official regulatory disclosures filed with the BSE Limited and National Stock Exchange of India.